基于虚拟查和细胞实验的SGLT2抑制剂查
Dan Liu1, Lei Yu2,3, Mei Ling Cao1
1Inner Mongolia Medical University, Hohhot, People's Republic of China.
Scientific reports
|August 26, 2025
概括
研究人员通过虚拟选和分子对接确定了13种抑制-葡萄糖携带体2 (SGLT2) 的有效化合物. 通过降低葡萄糖吸收, 这些化合物被认为是糖尿病的新疗法.
科学领域:
- 医学化学
- 计算机药物发现
- 药理学
背景情况:
- 二型糖尿病 (T2DM) 是一个全球性的健康问题,需要新的治疗策略.
- - 葡萄糖共传递剂2 (SGLT2) 抑制剂是抗糖尿病药物的关键类别.
- 开发具有提高疗效和特异性的新SGLT2抑制剂至关重要.
研究的目的:
- 通过计算和实验方法识别新型的SGLT2抑制剂.
- 评估已确定的化合物对SGLT2的抑制潜力.
- 探索被击中化合物与SGLT2蛋白的结合相互作用.
主要方法:
- 使用虚拟选和三维药模型进行初始化合物选择.
- 使用了定量结构活动关系 (QSAR) 建模.
- 为验证和相互作用分析,进行了生物测试 (293T细胞的葡萄糖吸收) 和分子对接.
主要成果:
- 最初通过虚拟查选择了20种化合物作为潜在的糖尿病治疗方法.
- 13种受影响的化合物表现出强烈的SGLT2抑制特性,其中化合物2的葡萄糖吸收率最低.
- 分子对接证实了受影响化合物和SGLT2之间的稳定,特定的结相互作用.
结论:
- 发现了13种具有显著SGLT2抑制活性的新化合物.
- 这些化合物具有作为治疗糖尿病的新药的潜力.
- 这项研究证实了药物发现的计算和实验方法的联合使用.
相关概念视频
Glucose Transporters
24.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.1K
Secondary Active Transport
7.6K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.6K
Glucose Absorption Into the Small Intestine
32.4K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
32.4K
Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
Methods for Studying Drug Absorption: In vitro
332
In vitro experiments are crucial for understanding the transport and absorption of drugs through biological materials. These studies employ varied methods such as the diffusion cell method, the everted sac technique, and the everted ring technique.
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...
332
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416


